Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231049 · ClinicalTrials.gov registry record · Phase 1
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
A Phase 1 study, sponsored by Agenus.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00231049 is a Phase 1 study that has completed, run by Agenus. The registered enrollment target is 35 participants.
The verdict
NCT00231049, a Phase 1 study, has completed, sponsored by Agenus.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a randomized, multi-center, sequential, dose-escalating study of three dose cohorts of AG-707. Individuals who meet all of the inclusion and exclusion criteria for eligibility will be randomized to receive either AG-707 (at the 80 µg dose), AG-707 with QS-21 (at the 80 µg dose), placebo, or QS-21. Each patient will be monitored for safety as specified in the protocol.
Interventions
- DRUG AG-707
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231049
The ClinicalTrials.gov registry entry for NCT00231049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-707 is the first listed.
NCT00231049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00231049 about?
NCT00231049 is a clinical study titled "Trial Evaluating Safety, Tolerability and Immune Response of AG-707". This is a randomized, multi-center, sequential, dose-escalating study of three dose cohorts of AG-707. Individuals who meet all of the inclusion and exclusion criteria for eligibility will be randomized to receive either AG-707 (at the 80 µg dose), AG-707 with QS-21 (at the 80 µg dose), placebo, or ...
What is the current status of trial NCT00231049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2006-03.
What interventions are being tested in trial NCT00231049?
The interventions under investigation include: AG-707 (DRUG).
Who is sponsoring clinical trial NCT00231049?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.